A Phase 1/2 interventional study of Pomalidomide and Cisplatin in Carcinoma, Small Cell, sponsored by Celgene. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Carcinoma, Small Cell with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Carcinoma, Small Cell · United States.
Among the 40 studies in Carcinoma, Small Cell with a site in United States, this one is the 27th largest by enrollment of the 38 interventional ones that give a count, is the only one that started in 2008, is one of 7 in phase 1/2, and was the 14th registered.
69 studies on the registry are indexed under Carcinoma, Small Cell; 13 are open to participants now.
Browse Carcinoma, Small Cell studies →3 of the 40 studies in Carcinoma, Small Cell with a site in United States are open now. Recruiting first, the newest first:
SystImmune Inc. · Sites in United States, Australia, Bulgaria and 13 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Andarix Pharmaceuticals · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Carcinoma, Small Cell studies recruiting now, 6 set no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 26 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 38 across 61 interventional studies indexed under Carcinoma, Small Cell.
Median enrollment 36 across the 38 interventional studies, 120 across the 2 observational. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
Bristol-Myers Squibb has 1 study filed under Carcinoma, Small Cell — fewer than ten, so there is no comparison to draw.
3 of the studies in Carcinoma, Small Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03333616Dana-Farber Cancer InstituteNivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | 2026-12-30 |
| NCT04560972City of Hope Medical CenterLB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer | 2027-01-27 |
| NCT04696575Roswell Park Cancer InstituteLamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Carcinoma, Small Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral pomalidomide 1 mg - 5 mg daily (QD) for 14 consecutive days of a 21-day cycle, in combination with intravenous (IV) cisplatin 25 mg/m\^2 and IV etoposide 100 mg/m\^2 on Days 1, 2 and 3 of each cycle during the dose-finding phase (Treatment and Extension Periods; 6 cycles in total). Dose escalation followed a standard phase 1 3+3 design. Participants continuing took only their pomalidomide dose (monotherapy) for an additional 3-week Recovery Period (14 days of consecutive dosing followed by 7 days of no study medication). Participants continuing took oral pomalidomide 5 mg QD as monotherapy for 14 consecutive days of each 21-day cycle until disease progression in the Maintenance Phase.
Drug: Pomalidomide · Drug: Cisplatin · Drug: Etoposide
Also known as: CC-4047, Pomalyst
Also known as: Cisplatinum, CDDP, Platin
Also known as: Etoposide phosphate, VP-16, Etopophos
Maximum Tolerated Dose (MTD)
The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle of treatment. The MTD Phase included the Treatment period (Cycle 1: Identification of the MTD) and the Extension period (Cycles 2 to 6: Confirmation of Safety of the MTD). (See Secondary Outcome Measure 2 for data on DLTs.)
Time frame: Cycle 1 (21 days)
Number of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase
For the purposes of determining the MTD (see Primary Outcome Measure), a DLT was defined as any 1 or more of the following: inability to deliver all 3 doses of cisplatin and etoposide due to toxicity; inability to deliver 14 consecutive days of daily pomalidomide dosing because the participant did not tolerate the medication due to any of the following: ≥ grade 3 non-hematological toxicity (excluding alopecia) occurring before Day 14 of pomalidomide dosing; febrile neutropenia (absolute neutrophil count \[ANC\] \<1,000/µL and fever \>101ºF, core temperature); grade 4 neutropenia of ≥7 days duration with onset on or before Day 14 of pomalidomide dosing; platelet count \<25,000/µL occurring before Day 14 of pomalidomide dosing. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0, grades: 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death.
Time frame: Cycles 1 - 6 (21-day cycles)
Tumor Response Rate According to Response Evaluation Criteria in Solid Tumors (RECIST)
Investigator's best assessment of response based on RECIST criteria during the MTD phase. For target lesions: Complete Response (CR)=Disappearance of all target lesions; Partial Response (PR)=≥30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; Progressed Disease (PD)=≥20% increase in sum of LD of target lesions taking as reference the smallest sum LD recorded since treatment started or the appearance of ≥1 new lesions; Stable Disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since treatment started. For non-target lesions: CR= Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/SD=Persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits; PD=Appearance of ≥1 new lesions; unequivocal progression of existing non-target lesions.
Time frame: Cycles 1 -6 (21-day cycles)
Duration of Response
Duration of Response was calculated from first Partial Response (PR) or Complete Response (CR) to disease progression. Duration of response was censored at the last date that the participant was known to be progression-free for: 1) participants who had not progressed at the time of analysis; 2) participants who had been removed from the treatment phase prior to documentation of progression.
Time frame: From first Partial Response (PR) or Complete Response (CR) to disease progression (maximum of 19.4 weeks)
Overall Survival
Overall Survival was defined as time (in weeks) from enrollment to death. The median is based on Kaplan-Meier estimate, with 95% confidence intervals about the median overall survival. Overall survival was censored at the last time participant was known to be alive for those who were alive at time of analysis.
Time frame: From enrollment through study termination (approximately 35 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the MTD (Combination Treatment) Phase
Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death.
Time frame: Cycles 1-6 (21-day cycles). Median (full range) duration of exposure (in weeks) to pomalidomide (MTD Phase): 1 mg, 17.9 (1.0, 20.3); 3 mg, 17.0 (16.9, 22.0); 4 mg, 14.0 (0.7, 22.0); 5 mg, 13.0 (2.0, 22.1). Cisplatin and etoposide: 15.3 (0.4, 20.6).
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Recovery Period or Maintenance (Monotherapy) Phase
Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. 'Related' = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death.
Time frame: Cycle 7 to discontinuation (21-day cycles). Median (full range) duration of exposure (in weeks) to pomalidomide during Maintenance Phase was 5.0 (1.1, 36.0).
| Milestone | Pomalidomide (Overall) |
|---|---|
| Started | 22 |
| Intent-to-treat (itt) populaton | 22 |
| Safety population | 22 |
| Completed | 17 |
| Not completed | 5 |
| Milestone | Pomalidomide (Overall) |
|---|---|
| Started | 17 |
| Completed | 11 |
| Not completed | 6 |
| Milestone | Pomalidomide (Overall) |
|---|---|
| Started | 11 |
| Completed | 3 |
| Not completed | 8 |
| Milestone | Pomalidomide (Overall) |
|---|---|
| Started | 8 |
| Completed | 0 |
| Not completed | 8 |
The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle of treatment. The MTD Phase included the Treatment period (Cycle 1: Identification of the MTD) and the Extension period (Cycles 2 to 6: Confirmation of Safety of the MTD). (See Secondary Outcome Measure 2 for data on DLTs.)
| mg | Pomalidomide (Overall) |
|---|---|
| Maximum Tolerated Dose (MTD) | 4 |
For the purposes of determining the MTD (see Primary Outcome Measure), a DLT was defined as any 1 or more of the following: inability to deliver all 3 doses of cisplatin and etoposide due to toxicity; inability to deliver 14 consecutive days of daily pomalidomide dosing because the participant did not tolerate the medication due to any of the following: ≥ grade 3 non-hematological toxicity (excluding alopecia) occurring before Day 14 of pomalidomide dosing; febrile neutropenia (absolute neutrophil count \[ANC\] \<1,000/µL and fever \>101ºF, core temperature); grade 4 neutropenia of ≥7 days duration with onset on or before Day 14 of pomalidomide dosing; platelet count \<25,000/µL occurring before Day 14 of pomalidomide dosing. National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), Version 4.0, grades: 1=mild, 2=moderate, 3=severe, 4=life threatening, 5=death.
| participants | Pomalidomide 1 mg | Pomalidomide 3 mg | Pomalidomide 4 mg | Pomalidomide 5 mg |
|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) During the MTD Phase | 1 | 0 | 0 | 2 |
Investigator's best assessment of response based on RECIST criteria during the MTD phase. For target lesions: Complete Response (CR)=Disappearance of all target lesions; Partial Response (PR)=≥30% decrease in sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; Progressed Disease (PD)=≥20% increase in sum of LD of target lesions taking as reference the smallest sum LD recorded since treatment started or the appearance of ≥1 new lesions; Stable Disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum LD since treatment started. For non-target lesions: CR= Disappearance of all non-target lesions and normalization of tumor marker level; Incomplete Response/SD=Persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits; PD=Appearance of ≥1 new lesions; unequivocal progression of existing non-target lesions.
| participants | Pomalidomide 1 mg | Pomalidomide 3 mg | Pomalidomide 4 mg | Pomalidomide 5 mg | Pomalidomide (Overall, MTD Phase) |
|---|---|---|---|---|---|
| Complete Response | 0 | 0 | 0 | 0 | 0 |
| Partial Response | 3 | 3 | 2 | 3 | 11 |
| No Change/Stable Disease | 0 | 0 | 0 | 0 | 0 |
| Progressive Disease | 1 | 1 | 1 | 1 | 4 |
| Not Assessed | 0 | 0 | 1 | 0 | 1 |
| Missing | 2 | 0 | 2 | 2 | 6 |
Duration of Response was calculated from first Partial Response (PR) or Complete Response (CR) to disease progression. Duration of response was censored at the last date that the participant was known to be progression-free for: 1) participants who had not progressed at the time of analysis; 2) participants who had been removed from the treatment phase prior to documentation of progression.
| weeks | Pomalidomide (Overall) |
|---|---|
| Duration of Response | 13.2 ± 5.54 |
Overall Survival was defined as time (in weeks) from enrollment to death. The median is based on Kaplan-Meier estimate, with 95% confidence intervals about the median overall survival. Overall survival was censored at the last time participant was known to be alive for those who were alive at time of analysis.
| weeks | Pomalidomide (Overall) |
|---|---|
| Overall Survival | 49.6 (28.0 to 63.9) |
Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. Serious adverse event (SAE) = any AE which: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. Related = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death.
| participants | Pomalidomide 1 mg | Pomalidomide 3 mg | Pomalidomide 4 mg | Pomalidomide 5 mg | Pomalidomide (Overall, MTD Phase) |
|---|---|---|---|---|---|
| ≥1 TEAE | 6 | 4 | 6 | 6 | 22 |
| ≥1 TEAE related to pomalidomide (POM) | 6 | 4 | 6 | 6 | 22 |
| ≥1 TEAE related to cisplatin and/or etoposide(C/E) | 6 | 4 | 6 | 6 | 22 |
| ≥1 Grade 3 or higher (GR3+) TEAE | 6 | 4 | 6 | 6 | 22 |
| ≥1 GR 3+ TEAE related to POM | 3 | 2 | 4 | 5 | 14 |
| ≥1 GR 3+ TEAE related to C/E | 6 | 3 | 6 | 5 | 20 |
| ≥1 Serious TEAE | 3 | 1 | 3 | 3 | 10 |
| ≥1 Serious TEAE related to POM | 2 | 1 | 1 | 3 | 7 |
| ≥1 Serious TEAE related to C/E | 2 | 1 | 3 | 3 | 9 |
| ≥1 TEAE leading to (→) withdrawal of POM | 2 | 0 | 2 | 2 | 6 |
| ≥1 TEAE → withdrawal of C/E | 2 | 1 | 1 | 2 | 6 |
| ≥1 TEAE → dose reduction/interruption of POM | 5 | 2 | 4 | 4 | 15 |
| ≥1 TEAE → dose reduction/interruption of C/E | 3 | 3 | 3 | 4 | 13 |
Adverse event (AE) = any noxious, unintended, or untoward medical occurrence occurring at any dose that may appear or worsen in a participant during the course of a study, including new intercurrent illness, worsening concomitant illness, injury, or any concomitant impairment of participant's health, including laboratory test values, regardless of etiology. TEAE = any AE occurring or worsening on or after the first treatment with any study drug. 'Related' = suspected by investigator to be related to study treatment. National Cancer Institute \[NCI\] Common Toxicity Criteria for Adverse Events \[CTCAE\], Version 4.0, grades: 1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, 5 = death.
| participants | Pomalidomide (Overall) |
|---|---|
| ≥1 TEAE | 9 |
| ≥1 TEAE related to pomalidomide (POM) | 8 |
| ≥1 TEAE related to cisplatin and/or etoposide (C/E | 7 |
| ≥1 Grade 3 or higher (GR3+) TEAE | 6 |
| ≥1 GR 3+ TEAE related to POM | 2 |
| ≥1 GR 3+ TEAE related to C/E | 2 |
| ≥1 TEAE → dose reduction/interruption of POM | 2 |
Collected over Treatment-emergent adverse events (TEAEs) were defined as any AE occurring or worsening on or after the first treatment of the study medication and within 30 days after the last dose. See Additional Description for duration of exposure for each treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pomalidomide 1 mg | — | 3/6 (50%) | 6/6 (100%) |
| Pomalidomide 3 mg | — | 1/4 (25%) | 4/4 (100%) |
| Pomalidomide 4 mg | — | 3/6 (50%) | 6/6 (100%) |
| Pomalidomide 5 mg | — | 3/6 (50%) | 6/6 (100%) |
| Pomalidomide (Overall) | — | 10/22 (45.5%) | 22/22 (100%) |
| Event | Pomalidomide 1 mg | Pomalidomide 3 mg | Pomalidomide 4 mg | Pomalidomide 5 mg | Pomalidomide (Overall) |
|---|---|---|---|---|---|
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/6 | 0/4 | 2/6 | 0/6 | 2/22 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/6 | 1/4 | 0/6 | 1/6 | 2/22 |
| Atrioventricular Block CompleteCardiac disorders | 0/6 | 0/4 | 0/6 | 1/6 | 1/22 |
| Diverticular PerforationGastrointestinal disorders | 0/6 | 0/4 | 0/6 | 1/6 | 1/22 |
| FatigueGeneral disorders | 1/6 | 0/4 | 0/6 | 0/6 | 1/22 |
| Neutropenic InfectionInfections and infestations | 1/6 | 0/4 | 0/6 | 1/6 | 2/22 |
| SepsisInfections and infestations | 1/6 | 0/4 | 0/6 | 0/6 | 1/22 |
| Blood Creatinine IncreasedInvestigations | 0/6 | 0/4 | 1/6 | 0/6 | 1/22 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/6 | 0/4 | 0/6 | 0/6 | 1/22 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/6 | 0/4 | 0/6 | 0/6 | 1/22 |
| Event | Pomalidomide 1 mg | Pomalidomide 3 mg | Pomalidomide 4 mg | Pomalidomide 5 mg | Pomalidomide (Overall) |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 5/6 | 4/4 | 6/6 | 6/6 | 21/22 |
| NauseaGastrointestinal disorders | 3/6 | 2/4 | 5/6 | 5/6 | 15/22 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/6 | 3/4 | 1/6 | 5/6 | 12/22 |
| NeutropeniaBlood and lymphatic system disorders | 3/6 | 2/4 | 3/6 | 5/6 | 13/22 |
| Peripheral sensory neuropathyNervous system disorders | 2/6 | 3/4 | 2/6 | 2/6 | 9/22 |
| ConstipationGastrointestinal disorders | 3/6 | 2/4 | 4/6 | 4/6 | 13/22 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/6 | 1/4 | 4/6 | 2/6 | 9/22 |
| HeadacheNervous system disorders | 0/6 | 0/4 | 4/6 | 0/6 | 4/22 |
| Decreased appetiteMetabolism and nutrition disorders | 2/6 | 2/4 | 4/6 | 0/6 | 8/22 |
| Oedema peripheralGeneral disorders | 2/6 | 1/4 | 3/6 | 3/6 | 9/22 |
Safety Population
| Age, Continuous(years) | Pomalidomide (Overall) |
|---|---|
| Mean | 63.9 ± 8.76 |
| Sex: Female, Male(Participants) | Pomalidomide (Overall) |
|---|---|
| Female | 4 |
| Male | 18 |
| Race/Ethnicity, Customized(participants) | Pomalidomide (Overall) |
|---|---|
| Caucasian (White) | 22 |
| Non-caucasian | 0 |
Ran from Feb 2008 to primary completion in Nov 2010, 33 months.
Results were first posted in Apr 2013, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pomalidomide